Chorvat RJ, Bakthavatchalam R, Beck JP, Gilligan PJ, Wilde RG, Cocuzza AJ, Hobbs FW, Cheeseman RS, Curry M, Rescinito JP, Krenitsky P, Chidester D, Yarem JA, Klaczkiewicz JD, Hodge CN, Aldrich PE, Wasserman ZR, Fernandez CH, Zaczek R, Fitzgerald LW, Huang SM, Shen HL, Wong YN, Chien BM, Arvanitis A. Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.
J Med Chem 1999;
42:833-48. [PMID:
10072681 DOI:
10.1021/jm980224g]
[Citation(s) in RCA: 56] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The synthesis and CRF receptor binding affinities of several new series of N-aryltriazolo- and -imidazopyrimidines and -pyridines are described. These cyclized systems were prepared from appropriately substituted diaminopyrimidines or -pyridines by nitrous acid, orthoester, or acyl halide treatment. Variations of amino (ether) pendants and aromatic substituents have defined the structure-activity relationships of these series and resulted in the identification of a variety of high-affinity agents (Ki's < 10 nM). On the basis of this property and lipophilicity differences, six of these compounds (4d,i,n,x, 8k, 9a) were initially chosen for rat pharmacokinetic (PK) studies. Good oral bioavailability, high plasma levels, and duration of four of these compounds (4d,i,n,x) prompted further PK studies in the dog following both iv and oral routes of administration. Results from this work indicated 4i,x had properties we believe necessary for a potential therapeutic agent, and 4i1 has been selected for further pharmacological studies that will be reported in due course.
Collapse